Target intelligence / Profile preview

ARHGEF26 antisense RNA 1 (ARHGEF26-AS1)

Target: ARHGEF26-AS1
Molecular classification: Long non-coding RNA (lncRNA), Other

Overview

ARHGEF26-AS1 is a long non-coding RNA (lncRNA) located on chromosome 3q25.2, transcribed antisense to the ARHGEF26 gene[1][3]. While ARHGEF26 encodes a guanine nucleotide exchange factor involved in Rho GTPase activation and cellular membrane dynamics[5], ARHGEF26-AS1 regulates ARHGEF26 expression through antisense interactions[1]. ARHGEF26-AS1 has been implicated in cancer biology, serving as an independent predictor of survival in colorectal cancer and intrahepatic cholangiocarcinoma and is included in prognostic models for glioma based on autophagy-related lncRNAs[1][6]. Research on ARHGEF26-AS1 is ongoing, with its functions and disease associations primarily documented in cancer contexts; currently, it is not considered a druggable therapeutic target and lacks direct pharmacological interventions[1][3][6].

Other names: ARHGEF26 antisense RNA 1 (non-protein coding)ARHGEF26-AS1

Biological functions

Modulation of gene expression (specifically regulating ARHGEF26)Involvement in tumorigenesis and cancer prognosisPotential regulator of autophagy and ferroptosis pathways

Disease associations

Cancer, including colorectal cancer, intrahepatic cholangiocarcinoma, and possibly low-grade gliomaTumorigenesis (general role inferred from association with cancer-related pathways)

Biomarkers

Potential prognostic marker in colorectal cancer and intrahepatic cholangiocarcinomaIncluded in autophagy-related lncRNA prognostic model for low-grade glioma

Beyond the preview

Go deeper on ARHGEF26 antisense RNA 1 (ARHGEF26-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARHGEF26 antisense RNA 1 (ARHGEF26-AS1).

Explore the full profile